These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9776504)

  • 1. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial.
    Amadori D; Frassineti GL; De Matteis A; Mustacchi G; Santoro A; Cariello S; Ferrari M; Nascimben O; Nanni O; Lombardi A; Scarpi E; Zoli W
    Breast Cancer Res Treat; 1998 Jun; 49(3):209-17. PubMed ID: 9776504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial.
    Dogliotti L; Berruti A; Buniva T; Zola P; Baù MG; Farris A; Sarobba MG; Bottini A; Alquati P; Deltetto F; Gosso P; Monzeglio C; Moro G; Sussio M; Perroni D
    J Clin Oncol; 1996 Apr; 14(4):1165-72. PubMed ID: 8648371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
    Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG).
    Buccheri G; Ferrigno D
    Eur J Cancer; 1994; 30A(10):1424-31. PubMed ID: 7833096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer.
    Buccheri G; Ferrigno D; Rosso A
    Cancer; 1993 Sep; 72(5):1564-72. PubMed ID: 8394198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
    Papaldo P; Lopez M; Cortesi E; Cammilluzzi E; Antimi M; Terzoli E; Lepidini G; Vici P; Barone C; Ferretti G; Di Cosimo S; Nistico C; Carlini P; Conti F; Di Lauro L; Botti C; Vitucci C; Fabi A; Giannarelli D; Marolla P
    J Clin Oncol; 2003 Sep; 21(18):3462-8. PubMed ID: 12972521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM).
    Gebbia V; Borsellino N; Testa A; Latteri MA; Milia V; Valdesi M; Giotta F; Gebbia N; Colucci G
    Anticancer Drugs; 1997 Nov; 8(10):943-8. PubMed ID: 9436637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.
    Pacini P; Rinaldini M; Algeri R; Guarneri A; Tucci E; Barsanti G; Neri B; Bastiani P; Marzano S; Fallai C
    Eur J Cancer; 2000 May; 36(8):966-75. PubMed ID: 10885599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer.
    Lopez M; Vici P; Di Lauro L; Paoletti G; Gionfra T; Conti F; Carpano S; Pignatti F; Giannarelli D
    Eur J Cancer; 1995 Sep; 31A(10):1611-4. PubMed ID: 7488410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lonidamine in high-risk breast cancer patients.
    Possinger K; Wagner H; Kovacs S; Flath B; Classen S; Wilmanns W
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):58-61. PubMed ID: 2031199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
    Ianniello GP; De Cataldis G; Comella P; Scarpati MD; Maiorino A; Brancaccio L; Cioffi R; Lombardi A; Carnicelli P; Tinessa V
    Cancer; 1996 Jul; 78(1):63-9. PubMed ID: 8646728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lonidamine plus cyclophosphamide in the treatment of adanced non-small cell lung cancer in the elderly: a phase II study.
    Salvati F; Antilli A; Cruciani AR; Lombardi A; Mugnaini L; Nunziati F; Perrone N; Portalone L; Signora M
    Tumori; 1995; 81(1):48-51. PubMed ID: 7754542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.
    Berruti A; Bitossi R; Gorzegno G; Bottini A; Alquati P; De Matteis A; Nuzzo F; Giardina G; Danese S; De Lena M; Lorusso V; Farris A; Sarobba MG; DeFabiani E; Bonazzi G; Castiglione F; Bumma C; Moro G; Bruzzi P; Dogliotti L;
    J Clin Oncol; 2002 Oct; 20(20):4150-9. PubMed ID: 12377958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.
    Norris B; Pritchard KI; James K; Myles J; Bennett K; Marlin S; Skillings J; Findlay B; Vandenberg T; Goss P; Latreille J; Rudinskas L; Lofters W; Trudeau M; Osoba D; Rodgers A
    J Clin Oncol; 2000 Jun; 18(12):2385-94. PubMed ID: 10856098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck.
    Colella E; Merlano M; Blengio F; Angelini F; Ausili Cefaro GP; Scasso F; Lo Russo V; Cirulli S; Giannarelli D; Cognetti F
    Eur J Cancer; 1994; 30A(7):928-30. PubMed ID: 7946585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer.
    Hardenbergh PH; Recht A; Gollamudi S; Come SE; Hayes DF; Shulman LN; O'Neill A; Gelman RS; Silver B; Harris JR
    Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):69-72. PubMed ID: 10477008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study.
    Robins HI; Neuberg DS; Benson AB; Pandya KJ; Tormey DC
    Invest New Drugs; 1990 Nov; 8(4):397-9. PubMed ID: 2084074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
    De Lena M; Lorusso V; Bottalico C; Brandi M; De Mitrio A; Catino A; Guida M; Latorre A; Leone B; Vallejo C; Gargano G
    J Clin Oncol; 1997 Oct; 15(10):3208-13. PubMed ID: 9336357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19.
    Liu J; Tu D; Dancey J; Reyno L; Pritchard KI; Pater J; Seymour LK
    Breast Cancer Res Treat; 2006 Dec; 100(3):263-71. PubMed ID: 16823511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.